Post-baseline responses for time to first occurrence of MACE, CV death, nonfatal MI, nonfatal stroke, hospitalization for unstable angina or heart failure, revascularization, and change from baseline in HbA 1c and body weight were analyzed using a mixed model for repeated measurements with interaction between subgroup, randomized treatment, and baseline value as covariate
Lamon, Sverine, et al
GLP-1 medications have demonstrated effects beyond weight loss that are directly relevant to Medicare's covered disease populations: reductions in cardiovascular events in patients with established heart disease (Wegovy's FDA approval for cardiovascular risk reduction), improvements in blood sugar control, reductions in sleep apnea severity, and improvements in kidney function
The underlying pathology for ASD is likely heterogeneous, and individuals would be expected to have varying responses to therapies
Post-sexual activity urination
Semaglutide exposed to room temperature for a few hours may still be safe, but overnight exposure carries significant risk of peptide degradation
